51,744 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in United Therapeutics Co. (NASDAQ:UTHRFree Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 51,744 shares of the biotechnology company’s stock, valued at approximately $18,257,000. Raymond James Financial Inc. owned 0.12% of United Therapeutics at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Oregon Public Employees Retirement Fund boosted its stake in shares of United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after purchasing an additional 39 shares during the period. MBM Wealth Consultants LLC raised its holdings in shares of United Therapeutics by 1.9% in the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after purchasing an additional 41 shares during the period. UMB Bank n.a. raised its holdings in shares of United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 51 shares during the period. Finally, Access Investment Management LLC raised its holdings in shares of United Therapeutics by 0.8% in the 4th quarter. Access Investment Management LLC now owns 7,335 shares of the biotechnology company’s stock valued at $2,588,000 after purchasing an additional 55 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 116,464 shares of company stock worth $42,396,244. Corporate insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

Get Our Latest Stock Report on UTHR

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $322.94 on Tuesday. The firm has a market cap of $14.50 billion, a price-to-earnings ratio of 14.18, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The company has a 50-day moving average of $349.12 and a 200 day moving average of $358.27.

United Therapeutics (NASDAQ:UTHRGet Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the firm posted $4.36 earnings per share. On average, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Articles

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.